StreetInsider.com News Articles

Piper Sandler Starts iRhythm Technologies (IRTC) at Overweight

Fri, 16 Oct 2026 04:24:01 -0400

Piper Sandler analyst Adam Maeder initiates coverage on iRhythm Technologies (NASDAQ: IRTC) with a Overweight rating and a price target of $160.00.

The analyst comments: “We are initiating coverage of iRhythm (Nasdaq: IRTC) with an Overweight rating and $160 PT, which ascribes a ~4.5x EV/Sales multiple to our ‘28E sales estimate. The stock has pulled back YTD due to a combination of factors, including implied decelerating growth in 2H, concerns around Zio MCT, as well as AI related fears. In our view, these concerns are overblown as IRTC has leadership in the large and growing LTCM segment, VitalPatch and Zio MCT

Piper Sandler Starts iRhythm Technologies (IRTC) at Overweight

Fri, 16 Oct 2026 04:24:01 -0400

Piper Sandler analyst Adam Maeder initiates coverage on iRhythm Technologies (NASDAQ: IRTC) with a Overweight rating and a price target of $160.00.

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 15 Oct 2026 16:05:00 -0400

SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the third quarter 2026 after the close of trading on Thursday, November 5, 2026. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Interested parties may access a live and archived webcast of the conference call on the “Quarterly Results” section of the company’s investor website

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

Thu, 15 Oct 2026 16:05:00 -0400

Interested parties may access a live and archived webcast of the conference call on the “Quarterly Results” section of the company’s investor website

iRhythm Technologies (IRTC) PT Lowered to $140 at Baird

Thu, 15 Oct 2026 07:22:27 -0400

Baird analyst David Rescott lowered the price target on iRhythm Technologies (NASDAQ: IRTC) to $140.00 (from $165.00) while maintaining a Outperform rating.

Form SCHEDULE 13G/A iRhythm Holdings, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Tue, 13 Oct 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20261013/27182141.html

iRhythm Technologies (IRTC) PT Lowered to $150 at Wells Fargo

Tue, 06 Oct 2026 05:45:46 -0400

Wells Fargo analyst Nathan Treybeck lowered the price target on iRhythm Technologies (NASDAQ: IRTC) to $150.00 (from $168.00) while maintaining a Overweight rating.

The analyst comments "We update our IRTC model following the deal close today. Our model now assumes ~ $18M of VitalPatch sales in Q4 and $83.5M in 2027. We assume some cannibalization of Zio AT / Zio MCT sales in 2027 and beyond. IRTC indicated that the deal closed earlier than it originally anticipated. This is the reason why the company did not provide 2027 color at deal close even after management said at our Healthcare conference that

iRhythm Technologies (IRTC) PT Lowered to $150 at Wells Fargo

Tue, 06 Oct 2026 05:45:46 -0400

Wells Fargo analyst Nathan Treybeck lowered the price target on iRhythm Technologies (NASDAQ: IRTC) to $150.00 (from $168.00) while maintaining a Overweight rating.

Form 8-K iRhythm Holdings, Inc. For: Oct 05

Mon, 05 Oct 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20261005/27146665.html

iRhythm completes $237.5M acquisition of VitalConnect

Mon, 05 Oct 2026 09:05:12 -0400

iRhythm Holdings, Inc. (Nasdaq: IRTC) announced the completion of its acquisition of VitalConnect, Inc., a wearable biosensor and ambulatory cardiac monitoring company, for $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet.

The transaction also included the issuance of up to 423,334 shares at closing. iRhythm provided an additional $10.0 million in working capital funding to VitalConnect between the signing and closing of the deal.

VitalConnect's platform supports multiple cardiac monitoring modalities, including mobile cardiac telemetry, and can monitor up to 11 physiological parameters. Its features include up to 30-day patient monitoring and four-in-one functionality across ambulatory, inpatient,

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

Mon, 05 Oct 2026 09:05:00 -0400

Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care.
iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect's growth and expand customer access.
Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027.

SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

Mon, 05 Oct 2026 09:05:00 -0400

Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care.
iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect's growth and expand customer access.
Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027.

iRhythm begins notifying patients after June 2026 data breach

Fri, 02 Oct 2026 16:51:34 -0400

iRhythm Holdings, Inc. (NASDAQ: IRTC) announced on Oct. 2, 2026, that it has begun notifying individuals affected by a cybersecurity incident first disclosed in June 2026, following the completion of a forensic investigation.

According to the company, unauthorized individuals accessed and downloaded data stored in certain third-party-hosted business applications between June 3 and June 8, 2026. iRhythm said it detected the unauthorized access on or around June 8, 2026, and activated its incident response plan.

The forensic review determined that the compromised data includes patient names, contact information such as addresses, email addresses, and phone numbers, iRhythm patient account numbers, device serial

iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026

Fri, 02 Oct 2026 16:41:00 -0400

SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC) today provided an update regarding the cybersecurity incident previously disclosed in June 2026. Following completion of the forensic investigation and subsequent review to determine the nature of the impacted data, the company has begun notifying impacted individuals.

As previously disclosed, on or around June 8, 2026, iRhythm detected unauthorized access in certain third-party-hosted business applications. Upon detecting the unauthorized access, iRhythm promptly implemented its incident response plan. As part of the investigation, iRhythm has been working very closely with external cybersecurity

iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026

Fri, 02 Oct 2026 16:41:00 -0400

Form 8-K iRhythm Holdings, Inc. For: Sep 22

Tue, 22 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260922/27091713.html

iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 16:05:00 -0400

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21^st Annual Healthcare Conference.

iRhythm’s management is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. ET. Interested parties may access a live and archived webcast of the fireside chat on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.

iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 16:05:00 -0400

SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21^st Annual Healthcare Conference.

iRhythm’s management is scheduled to present on Wednesday, September 9, 2026, at 8:45 a.m. ET. Interested parties may access a live and archived webcast of the fireside chat on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Holdings, Inc.

iRhythm Technologies (IRTC) PT Lowered to $190 at Freedom Capital

Thu, 20 Aug 2026 07:00:20 -0400

Freedom Capital analyst Gene Mannheimer lowered the price target on iRhythm Technologies (NASDAQ: IRTC) to $190.00 (from $200.00) while maintaining a Buy rating.
The analyst comments "We reiterate our Buy rating on IRTC following Q2 results that beat expectations for revenue and EBITDA. EBITDA margins were a record 19%, with opex holding flat sequentially. We do not see this repeating given investments expected in 2H, but management still raised its FY26 EBITDA guidance to 13-14% margin, up from 12-13%. We applaud the VitalConnect acquisition as the transaction adds 4:1 functionality to IRTC’s portfolio, takes out a formidable competitor and enables the

iRhythm Technologies (IRTC) PT Lowered to $190 at Freedom Capital

Thu, 20 Aug 2026 07:00:20 -0400

Freedom Capital analyst Gene Mannheimer lowered the price target on iRhythm Technologies (NASDAQ: IRTC) to $190.00 (from $200.00) while maintaining a Buy rating.
The analyst comments "We reiterate our Buy rating on IRTC following Q2 results that beat expectations for revenue and EBITDA. EBITDA margins were a record 19%, with opex holding flat sequentially. We do not see this repeating given investments expected in 2H, but management still raised its FY26 EBITDA guidance to 13-14% margin, up from 12-13%. We applaud the VitalConnect acquisition as the transaction adds 4:1 functionality to IRTC’s portfolio, takes out a formidable competitor and enables the

iRhythm Technologies (IRTC) PT Lowered to $168 at Wells Fargo

Tue, 18 Aug 2026 06:25:27 -0400
Wells Fargo analyst Nathan Treybeck lowered the price target on iRhythm Technologies (NASDAQ: IRTC) to $168.00 (from $180.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A iRhythm Holdings, Inc. Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:02:00 -0400
si-local-file:///var/storage/secattach/20260814/26924844.html

Form SCHEDULE 13G/A iRhythm Holdings, Inc. Filed by: RTW INVESTMENTS, LP

Fri, 14 Aug 2026 08:02:00 -0400
si-local-file:///var/storage/secattach/20260814/26924844.html

Form SCHEDULE 13G iRhythm Holdings, Inc. Filed by: Artisan Partners Limited Partnership

Thu, 13 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260813/26921843.html

Form SCHEDULE 13G iRhythm Holdings, Inc. Filed by: Artisan Partners Limited Partnership

Thu, 13 Aug 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260813/26921843.html